

Arianna Gentilini

London School of Economics | Cowdray House 2.06 | London WC2A2AE
a.gentilini@lse.ac.uk | +44 7706549539

Education

2020 – present	<i>ESRC-funded Ph.D. candidate, Health Policy and Economics</i> Provisional dissertation title: “The role of patient organisations in innovation and access in the rare disease space” Supervisors: Dr. Panos Kanavos, Prof. Alistair McGuire London School of Economics and Political Science
2017 – 2018	<i>M.Sc., International Health Policy and Health Economics, with distinction</i> Dissertation title: “Physical activity, diet or both to improve type 2 diabetes mellitus risk factors in diabetic and prediabetic adults: a network meta-analysis and microsimulation analysis” London School of Economics and Political Science
2013 – 2016	<i>B.Sc., International Economics, with honours</i> Università degli Studi di Padova

Employment

London	Medical Technology Research Group
2020 – present	London School of Economics and Political Science
2018 – 2020	<i>Senior Researcher</i> <i>Research Assistant</i>
	• Investigating factors behind misalignment between country reimbursement decisions and European Society of Medical Oncology ratings for oncology pharmaceutical products • Developed and analysed a database of compound-indication pairs, integrating HTA recommendation and funding decision data from national online databases • Examined factors affecting reimbursement decision timelines and decisions employing survival analysis and multinomial logistic regression techniques across a range of OECD countries • Submitted manuscripts for publication in high-impact peer-reviewed journals
London	Centre for Health Economics and Policy Innovation
2021 – 2022	Imperial College Business School <i>Visiting Fellow</i>
	• Collaborated with Professor Marisa Miraldo on a research project investigating the influence of rare disease patient organisations on medical innovation • Analysed a large panel of over 1.5 million observations, incorporating external data from primary and secondary sources • Utilized robust econometric techniques to empirically estimate the impact of patient organisations’ advocacy on R&D in rare diseases

London 2021 – 2022 2020 – 2021	Dolon Limited <i>Consultant</i> <i>Senior Analyst</i>	• Led policy project on combination pricing in oncology focusing on novel-novel combinations • Drafted narratives and propositions to communicate orphan products' value and support P&R submissions across a wide range of indications, including myelofibrosis, Pompe and Fabry diseases • Supported in the preparation, facilitation and reporting of advisory boards and workshops aimed at assessing payers perception of products' value propositions and evidence packages to advise launch strategies
London 2019 – 2020 2018 – 2019	Symmetron Limited <i>Associate Health Economist</i> <i>Health Economist</i>	• Adapted as well as developed from scratch budget impact and cost-effectiveness models for global headquarters and local country affiliates in various therapeutic areas including respiratory diseases, oncology and depression • Supported pharmaceutical companies in the reimbursement submission to health technology assessment authorities in Europe and China and in the post-submission phase • Interviewed key opinion leaders and conducted targeted literature reviews to collect health-related quality of life data, healthcare resource use and unit costs for country adaptations • Prepared draft manuscripts and posters for peer-reviewed publications and international conferences
London 2018 – 2018	S&P Global <i>Life Sciences Intern</i>	• Conducted a systematic review and network meta-analysis aiming at quantifying the expected benefits of physical activity alone or combined with a healthy diet in improving cardiovascular risk factors • Updated with the network meta-analysis' results the Disease Prevention Microsimulation Model, a Markov model that predicts the likelihood of a specific disease in a certain population as well as valuing the impact of a drug or prevention program, using R

Short-term consultancies

Washington, D.C. <i>(Remote)</i> 2023	World Bank	• Conducted a literature review on how pharmaceutical services have been leveraged for NCD service delivery in LMICs • Developed and analysed results from a pharmacist survey to gather insights on competencies readiness for delivering WHO PEN interventions in Zambia • Drafted a policy paper summarizing evidence on how pharmaceutical services can be deployed to deliver NCD interventions in Zambia, Congo and Senegal
--	-------------------	---

London **The Health Policy Partnership**

- 2022
- Conducted a literature review to understand the policy landscape for Wilson's disease at the national level in France and Italy
 - Drafted two country spotlight reports providing an overview of Wilson's disease unmet need in the country, policy gaps and challenges that may exist

Teaching

Seminar Leader **London School of Economics**
Introduction to Quantitative Analysis (2021-22)
Intermediate Quantitative Analysis (2021-22)
Pharmaceutical Economics and Policy (2023-2024)

Imperial College
Research Methods & Practice (2022-23)
Quantitative Methods (2022-23)
Health Economics (2023, marking only)
Health Care Financing (2023, marking only)

Class Teacher **LSE Health**
Market Access Academy, in collaboration with BCG (2023)

Publications

PEER-REVIEWED ARTICLES

Gentilini A, Miraldo M (2023). The Role of Patient Organisations in Research and Development: Evidence from Rare Diseases. *Social Science & Medicine*.
<https://doi.org/10.1016/j.socscimed.2023.116332>

Kanavos P, Visentin E, **Gentilini A** (2023). Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries. *Social Science & Medicine*.
<https://doi.org/10.1016/j.socscimed.2023.116045>

Gentilini A, Parvanova I (2023). Industry Funding of Patient Organisations in the United Kingdom: A Retrospective Study of Commercial Determinants, Funding Concentration and Disease Prevalence. *BMJ Open*; <http://dx.doi.org/10.1136/bmjopen-2022-071138>

Rinciog C, Diamanthopoulos A, **Gentilini A**, Bondue B, Dahlqvist C, Froidure A, Wuyts WA, Soulard S (2019). The Cost-Effectiveness of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium. *Pharmacoeconomics Open*. <https://doi.org/10.1007/s41669-019-00191-w>

REPORTS AND ABSTRACTS

Parvanova I, **Gentilini A**, Cushing J, Naci H (2023). Safeguarding NICE from patient groups' conflicts of interest. *BMJ*; <https://doi.org/10.1136/bmj.p1243>

Kamphuis B, Fontrier AM, Haig M, Politopoulou K, Salyga H, **Gentilini A**, Kanavos P (2022). Development of policies to increase headroom for innovation in Egypt and the Kingdom of Saudi Arabia. Available on [LSE Consulting website](#).

Neez E, **Gentilini A**, Hutchings A (2021). Addressing unmet needs in extremely rare and paediatric-onset diseases: how the biopharmaceutical innovation model can help identify current issues and find potential solutions. Available on [EFPIA website](#).

Gentilini A, Sawyer L, Langford B, Salih F, Murphy J. Cost-Effectiveness of Vagus Nerve Stimulation for Treatment-Resistant Depression in the United Kingdom (2020). Value in Health, Volume 23, S587. <https://doi.org/10.1016/j.jval.2020.08.1097>

Neez E, **Gentilini A**, Dutton R, Hutchings A. Estimated impact of EU Orphan Regulation on incentives for innovation (2020). Available on [Dolon website](#).

LeReun C, **Gentilini A**, Large S, Chowdury MHR, Smith TA, Rinciog C (2019). Network meta-analysis comparing palbociclib plus fulvestrant with everolimus plus exemestane for HR+/HER2-advanced breast cancer that has become resistant to previous endocrine therapy. Value in Health, Volume 22, S446. <https://doi.org/10.1016/j.jval.2019.09.252>

Conferences and seminars

Gentilini A, Miraldo M. “The Role of Patient Organisations on Research and Development: Evidence from Rare Diseases”, Accepted poster presentation, American-European Health Economics Study Group, 6-7 July 2023. Harvard Kennedy School, Cambridge MA, USA.

Gentilini A, Lombe K. “Leveraging pharmaceutical services to enhance NCD service delivery in LMICs: Insights and experiences from Zambia”, Accepted poster, World Non-Communicable Diseases Congress 2023, 26 June 2023. Toronto, Canada.

Gentilini A, Parvanova I. “Industry Funding of Patient Organisations in the United Kingdom: A Retrospective Study of Commercial Determinants, Funding Concentration and Disease Prevalence”, Invited speaker, The Connaught Global Challenge Award Seminar Series Presents, WHO Collaborating Center for Governance, Accountability and Transparency in the Pharmaceutical Sector, 2 March 2023, Toronto, Canada (Virtual).

Gentilini A. “Orphan drugs: current policies, challenges and future trends”, Invited speaker, University of Bari – Department of Economics Seminar Series, 29 November 2021, Bari, Italy (Virtual).

Media coverage

Shanti Das and Jon Ungood-Thomas. [Revealed: drug firms funding UK patient groups that lobby for NHS approval of medicines](#), The Observer, 23 July 2023 (Research referenced and quoted).

Languages & IT Skills

Languages: English (fluent), Italian (native), French (intermediate), and Spanish (Intermediate)

Computer Languages and Software: STATA, R, Excel, LaTeX, Endnote, WinBUGS, Grafula, DistillerSR, RevMan, WordPress, PolleEV, NVivo

Professional services

Ad-hoc reviewer BMJ
Health Policy